Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 26.177
Filtrar
1.
Top Curr Chem (Cham) ; 378(1): 13, 2020 Jan 10.
Artigo em Inglês | MEDLINE | ID: mdl-31925680

RESUMO

The use of magnetic nanoparticles (MNPs), such as iron oxide nanoparticles (IONPs), in biomedicine is considered to be a valuable alternative to the more traditional materials due to their chemical stability, cost-effectiveness, surface functionalization, and the possibility to selectively attach and transport targeted species to the desired location under a magnetic field. One of the many main applications of MNPs is DNA separation, which enables genetic material manipulation; consequently, MNPs are used in numerous biotechnological methods, such as gene transfection and molecular recognition systems. In addition, the interaction between the surfaces of MNPs and DNA molecules and the magnetic nature of the resulting composite have facilitated the development of safe and effective gene delivery vectors to treat significant diseases, such as cancer and neurological disorders. Furthermore, the special recognition properties of nucleic acids based on the binding capacity of DNA and the magnetic behavior of the nanoparticles allowing magnetic separation and concentration of analytes have led to the development of biosensors and diagnostic assays; however, both of these applications face important challenges in terms of the improvement of selective nanocarriers and biosensing capacity. In this review, we discuss some aspects of the properties and surface functionalization of MNPs, the interactions between DNA and IONPs, the preparation of DNA nanoplatforms and their biotechnological applications, such as the magnetic separation of DNA, magnetofection, preparation of DNA vaccines, and molecular recognition tools.


Assuntos
DNA/química , Compostos Férricos/química , Nanopartículas de Magnetita/química , Nanomedicina , DNA/isolamento & purificação , Portadores de Fármacos/química , Humanos , Neoplasias/diagnóstico , Neoplasias/tratamento farmacológico , Neoplasias/imunologia , Vacinas de DNA/química , Vacinas de DNA/imunologia
2.
BMJ ; 368: l6670, 2020 01 07.
Artigo em Inglês | MEDLINE | ID: mdl-31911452

RESUMO

Thyroid nodules are extremely common and can be detected by sensitive imaging in more than 60% of the general population. They are often identified in patients without symptoms who are undergoing evaluation for other medical complaints. Indiscriminate evaluation of thyroid nodules with thyroid biopsy could cause a harmful epidemic of diagnoses of thyroid cancer, but inadequate selection of thyroid nodules for biopsy can lead to missed diagnoses of clinically relevant thyroid cancer. Recent clinical guidelines advocate a more conservative approach in the evaluation of thyroid nodules based on risk assessment for thyroid cancer, as determined by clinical and ultrasound features to guide the need for biopsy. Moreover, newer evidence suggests that for patients with indeterminate thyroid biopsy results, a combined assessment including the initial ultrasound risk stratification or other ancillary testing (molecular markers, second opinion on thyroid cytology) can further clarify the risk of thyroid cancer and the management strategies. This review summarizes the clinical importance of adequate evaluation of thyroid nodules, focuses on the clinical evidence for diagnostic tests that can clarify the risk of thyroid cancer, and highlights the importance of considering the patient's values and preferences when deciding on management strategies in the setting of uncertainty about the risk of thyroid cancer.


Assuntos
Neoplasias/diagnóstico , Medição de Risco/métodos , Neoplasias da Glândula Tireoide/diagnóstico , Nódulo da Glândula Tireoide , Biópsia/métodos , Testes de Química Clínica , Diagnóstico Diferencial , Humanos , Achados Incidentais , Nódulo da Glândula Tireoide/diagnóstico por imagem , Nódulo da Glândula Tireoide/patologia
3.
J Enzyme Inhib Med Chem ; 35(1): 255-260, 2020 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31790601

RESUMO

Among the diagnostic techniques for the identification of tumour biomarkers, the liquid biopsy is considered one that offers future research on precision diagnosis and treatment of tumours in a non-invasive manner. The approach consists of isolating tumor-derived components, such as circulating tumour cells (CTC), tumour cell-free DNA (ctDNA), and extracellular vesicles (EVs), from the patient peripheral blood fluids. These elements constitute a source of genomic and proteomic information for cancer treatment. Within the tumour-derived components of the body fluids, the enzyme indicated with the acronym CA IX and belonging to the superfamily of carbonic anhydrases (CA, EC 4.2.1.1) is a promising aspirant for checking tumours. CA IX is a transmembrane-CA isoform that is strongly overexpressed in many cancers being not much diffused in healthy tissues except the gastrointestinal tract. Here, it is summarised the role of CA IX as tumour-associated protein and its putative relationship in liquid biopsyfor diagnosing and monitoring cancer progression.


Assuntos
Biomarcadores Tumorais/antagonistas & inibidores , Anidrase Carbônica IX/antagonistas & inibidores , Inibidores da Anidrase Carbônica/farmacologia , Neoplasias/diagnóstico , Animais , Biomarcadores Tumorais/metabolismo , Anidrase Carbônica IX/metabolismo , Inibidores da Anidrase Carbônica/química , Humanos , Biópsia Líquida , Neoplasias/enzimologia
4.
Recent Results Cancer Res ; 215: 77-88, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-31605224

RESUMO

Circulating tumor cells (CTCs) provide valuable information about the molecular evolution of cancers, as they may initially respond and ultimately progress on therapy. As intact tumor cells isolated from the bloodstream, CTCs also enable assessment of heterogeneous subpopulations, and their analysis may include DNA, RNA, and protein biomarkers. New microfluidic cell isolation strategies greatly facilitate the challenge of enriching viable tumor cells from the billions of hematopoietic cells within a standard blood specimen. While counting and characterization of enriched CTCs have primarily relied on immunostaining for tumor cell-specific antigens, new RNA-based analytic platforms are providing new insight into the identity of CTCs and providing new tools for clinical applications. Single-cell RNA sequencing of CTCs reveals a high degree of heterogeneity among cancer cells from a single individual, while new digital RNA-based amplification platforms may now allow high-sensitivity and high-throughput quantitative scoring of CTCs for clinical applications. Here, we focus on transcriptomic analysis of CTCs and its relevance in understanding metastatic cancer progression and in developing diagnostic assays to monitor cancer.


Assuntos
Separação Celular/métodos , Neoplasias/genética , Neoplasias/patologia , Células Neoplásicas Circulantes , RNA Neoplásico/análise , Progressão da Doença , Humanos , Neoplasias/diagnóstico , Células Neoplásicas Circulantes/metabolismo , RNA Neoplásico/genética
5.
Biochem Med (Zagreb) ; 30(1): 010501, 2020 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-31839719

RESUMO

The current scenario of in vitro and in vivo diagnostics can be summarized using the "silo metaphor", where laboratory medicine, pathology and radiology are three conceptually separated diagnostic disciplines, which will increasingly share many comparable features. The substantial progresses in our understanding of biochemical-biological interplays that characterize many human diseases, coupled with extraordinary technical advances, are now generating important multidisciplinary convergences, leading the way to a new frontier, called integrated diagnostics. This new discipline, which is currently defined as convergence of imaging, pathology and laboratory tests with advanced information technology, has an enormous potential for revolutionizing diagnosis and therapeutic management of human diseases, including those causing the largest number of worldwide deaths (i.e. cardiovascular disease, cancer and infectious diseases). However, some important drawbacks should be overcome, mostly represented by insufficient information technology infrastructures, costs and enormous volume of different information that will be integrated and delivered. To overcome these hurdles, some specific strategies should be defined and implemented, such as planning major integration of exiting information systems or developing innovative ones, combining bioinformatics and imaging informatics, using health technology assessment for assessing cost and benefits, providing interpretative comments in integrated reports, developing and using expert systems and neural networks, overcoming cultural and political boundaries for generating multidisciplinary teams and integrated diagnostic algorithms.


Assuntos
Doenças Cardiovasculares/diagnóstico , Neoplasias/diagnóstico , Sepse/diagnóstico , Biomarcadores/análise , Produtos de Degradação da Fibrina e do Fibrinogênio/análise , Humanos , Subunidade beta da Proteína Ligante de Cálcio S100/metabolismo , Tomografia , Troponina/análise
6.
Biomed Khim ; 65(6): 457-467, 2019 Oct.
Artigo em Russo | MEDLINE | ID: mdl-31876516

RESUMO

The main problems in the diagnostics and treatment of malignant tumors are early detection of the disease, prediction of the course of the disease and response to therapy. The solution may be associated with identification of biomarkers secreted by tumor cells within extracellular vesicles, known as exosomes. The study of exosome proteins attracts special attention, because their molecular composition can have information about tumor identity, and also represent a set of signaling molecules that regulate the processes of tumor progression and growth. In addition, the analysis of exosomes secreted into the extracellular space corresponds to the promising concept of a liquid biopsy. In this review, we have summarized the current experience in the molecular study of exosomes in various types of malignant tumors, including colorectal cancer, lung cancer, ovaries, prostate and breast cancer, with special emphasis on omics methods and outlined the prospects for their use in diagnosis.


Assuntos
Exossomos/metabolismo , Proteínas de Neoplasias/metabolismo , Neoplasias/diagnóstico , Biomarcadores Tumorais/metabolismo , Humanos , Proteômica
7.
Anticancer Res ; 39(11): 6035-6039, 2019 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-31704829

RESUMO

BACKGROUND/AIM: Low-density lipoproteins (LDL) are a heterogeneous class of particles that differ in size and density from each other. Small dense LDL (sdLDL) particles are considered more atherogenic than larger particles. The aim of the study was to evaluate serum levels of sdLDL in patients who died from cardiovascular diseases (CVD) or cancer in a cohort of patients followed up in the De Bellis Research Hospital for 20 years. PATIENTS AND METHODS: A total of 75 participants who died of cancer and 87 who died of CVD were enrolled and they were matched for age and sex with 135 healthy controls, i.e. without CVD or cancer and are still alive. RESULTS: Patients who died from cancer had the highest value of LDL IV subfraction (0.25±1.16), followed by those who died from CVD (0.17±0.96). CONCLUSION: The integrated profile of sdLDL between CVD and cancer suggests that therapeutic modulation of sdLDL may be associated with a risk reduction for these diseases.


Assuntos
Biomarcadores/sangue , Doenças Cardiovasculares/sangue , Doenças Cardiovasculares/diagnóstico , Lipoproteínas LDL/sangue , Neoplasias/sangue , Neoplasias/diagnóstico , Adulto , Idoso , Estudos de Casos e Controles , Feminino , Seguimentos , Humanos , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Prognóstico , Fatores de Risco
8.
Zhonghua Yu Fang Yi Xue Za Zhi ; 53(11): 1183-1187, 2019 Nov 06.
Artigo em Chinês | MEDLINE | ID: mdl-31683411

RESUMO

Lead-time bias and length bias were common systematic errors in observational screening studies, which might be a common cause of overstating or distorting the true screening effects. One of key concerns in observational screening studies was how to estimate the screening effects based on the consideration of these two biases. This paper illustrated how to identify and correct the lead-time bias using the tumor volume doubling time and the non-homogeneous Poisson process, and how to correct the length bias using a weighted method. The application conditions of each method were also discussed to present several useful toolboxes to correct the lead-time bias and length bias appropriately and evaluate the effectiveness of the cancer screening program accurately.


Assuntos
Viés , Detecção Precoce de Câncer , Programas de Rastreamento/métodos , Neoplasias/diagnóstico , Humanos , Tempo
9.
Rev Med Suisse ; 15(666): 1790-1794, 2019 Oct 09.
Artigo em Francês | MEDLINE | ID: mdl-31599519

RESUMO

Actinomycosis is a chronic bacterial infection, caused by the genus Actinomyces, commensal of the digestive and genital tract. The most common presentation of the disease affects the cervicofacial region, but other anatomical sites in the abdomen, thorax and central nervous system may be involved. Differential diagnosis includes neoplasia. Prolonged culture of deep samples in an anaerobic environment is the gold standard of the diagnosis. The treatment of choice is intravenous penicillin G followed by oral amoxicillin for a total duration of 6 to 12 months. However, depending on the location and response to antibiotics, shorter therapy may be considered.


Assuntos
Actinomicose/diagnóstico , Actinomicose/tratamento farmacológico , Actinomyces/patogenicidade , Actinomicose/microbiologia , Actinomicose/patologia , Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Diagnóstico Diferencial , Humanos , Neoplasias/diagnóstico , Especificidade de Órgãos
10.
Br J Radiol ; 92(1104): 20190672, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31603350

RESUMO

OBJECTIVE: This paper considers aspects of radiobiology and cell and tissue kinetics applicable to legal disputations concerned with diagnostic and treatment onset delays. METHODS: Various models for tumour volume changes with time are reviewed for estimating volume ranges at earlier times, using ranges of kinetic parameters. Statistical cure probability methods, using Poisson statistics with allowances for parameter heterogeneity, are also described to estimate the significance of treatment delays, as well as biological effective dose (BED) estimations of radiation effectiveness. RESULTS: The use of growth curves, based on parameters in the literature but with extended ranges, can identify a window of earlier times when such tumour volumes would be amenable to a cure based on the literature for curability with stage (and dimensions). Also, where tumour dimensions are not available in a post-operative setting, higher cure probabilities can be achieved if treatment had been given at earlier times. CONCLUSION: The use of radiobiological modelling can provide useful insights, with quantitative assessments of probable prior conditions and future outcomes, and thus be of assistance to a Court in deciding the most correct judgement. ADVANCES IN KNOWLEDGE: This study collates prior knowledge about aspects of radiobiology that can be useful in the accumulation of sufficient proof within medicolegal claims involving diagnostic and treatment days.


Assuntos
Diagnóstico Tardio/legislação & jurisprudência , Neoplasias/diagnóstico , Neoplasias/radioterapia , Radiobiologia/legislação & jurisprudência , Tempo para o Tratamento/legislação & jurisprudência , Algoritmos , Biomarcadores Tumorais/análise , Ciclo Celular/fisiologia , Proliferação de Células/fisiologia , Humanos , Estadiamento de Neoplasias , Neoplasias/patologia , Distribuição de Poisson , Resolução de Problemas , Prognóstico , Radioterapia (Especialidade)/legislação & jurisprudência , Radioterapia (Especialidade)/métodos , Radiobiologia/métodos , Eficiência Biológica Relativa , Fatores de Tempo , Carga Tumoral/fisiologia
11.
Tumour Biol ; 41(10): 1010428319881344, 2019 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-31608792

RESUMO

MicroRNAs are a family of small, single-stranded RNAs that have key roles in regulating multiple signaling pathways within a cell. Studies have implicated aberrant expression of microRNAs in the development and progression of several pathologies including cancer. MicroRNAs are relatively stable and readily available in body fluids and tissues, making them desirable biomarkers for prognostic and diagnostic purposes in an array of diseases. MicroRNA 628 (5p/3p variants) is located in the 15q21.3 cancer-related region, and evidence suggests its association with various pathologies. The -5p mature variant, microRNA 628-5p, has been reported to be differentially expressed in various cancers, and its expression has been mostly associated with tumor suppression but there are few reports identifying its role in cancer progression. Several studies have also suggested its utility in diagnosis and prognosis of various cancers. Dysregulation of microRNA 628-5p has also been implicated in embryonal implantation defects, autism, immune modulation, myogenesis, cardiovascular disease, viral infection, and skeletal muscle repair. Here, we have provided a comprehensive review on available literature explaining the role of microRNA 628-5p as a potential cancer biomarker as well as briefly describe its function in other diseases and normal physiological conditions.


Assuntos
Biomarcadores/análise , Regulação Neoplásica da Expressão Gênica , MicroRNAs/genética , Neoplasias/diagnóstico , Neoplasias/genética , Animais , Humanos , MicroRNAs/análise , Prognóstico , Transdução de Sinais
13.
Adv Exp Med Biol ; 1164: 47-61, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31576539

RESUMO

Stem cell antigen-1 (Sca-1) is the first identified member of mouse Ly6 gene family. We discovered that Sca-1 disrupts TGFß signaling and enhances mammary tumorigenesis in a DMBA-induced mammary tumor model. Sca-1 gene is lost during evolution in humans. Human Ly6 genes Ly6D, LyE, LyH, and LyK on human chromosome 8q24.3 genes are syntenic to the mouse chromosome 15 where Sca-1 is located. We found that Ly6D, E, H, and K are upregulated in human cancer compared to normal tissue and that the increased expression of these genes are associated with poor prognosis of multiple types of human cancer. Several other groups have indicated increased expression of Ly6 genes in human cancer. Here we described the relevance of expression of human Ly6D, LyE, LyH, and LyK in functioning of normal tissues and tumor progression.


Assuntos
Antígenos Ly , Biomarcadores , Regulação Neoplásica da Expressão Gênica , Neoplasias , Animais , Antígenos Ly/genética , Biomarcadores/metabolismo , Transformação Celular Neoplásica , Humanos , Neoplasias/diagnóstico , Neoplasias/genética , Prognóstico
14.
Medicine (Baltimore) ; 98(40): e17439, 2019 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-31577764

RESUMO

BACKGROUND: Speckle-type POZ protein (SPOP) has recently been reported as a prognostic tumor biomarker. However, the predictive value of SPOP remains controversial in human cancers. The current meta-analysis was performed to obtain a comprehensive evaluation of the relationship between SPOP expression and prognosis of cancer patients. METHODS: Embase, Pubmed, Web of Science, and Chinese Biomedical Literature database were systematically searched up to January 2, 2019. The pooled hazard ratios (HRs) and/or pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to quantitatively assess the relationship of SPOP expression with prognosis and lymph node metastasis (LNM). RESULTS: A total of 9 studies with 928 patients were included in this meta-analysis. The results showed that low SPOP expression was significantly related to poor overall survival (high/low: HR = 0.55; 95% CI: 0.38-0.79, P = .001), especially for digestive system cancers (high/low: HR = 0.46; 95% CI: 0.27-0.78, P = .003). However, SPOP expression did not affect progression-free survival in cancer patients (high/low: HR = 2.07; 95% CI: 0.16-26.70, P = .578). Additionally, the association between SPOP overexpression and LNM was positive in patients with clear cell renal cell carcinoma (ccRCC) (OR = 5.26; 95% CI: 1.66-16.68, P = .005) but negative in cancer patients without ccRCC (OR = 0.36; 95% CI: 0.21-0.62, P < .001). CONCLUSION: Decreased SPOP expression could predict poor prognosis of cancer patients, suggesting that SPOP protein may be a useful prognostic biomarker in cancer patients.


Assuntos
Metástase Linfática/diagnóstico , Neoplasias/diagnóstico , Neoplasias/metabolismo , Proteínas Nucleares/metabolismo , Proteínas Repressoras/metabolismo , Humanos , Neoplasias/mortalidade , Valor Preditivo dos Testes , Prognóstico
15.
Mol Biol (Mosk) ; 53(5): 774-789, 2019.
Artigo em Russo | MEDLINE | ID: mdl-31661477

RESUMO

Interleukin-33 (IL-33) belongs to the IL-1 cytokine family and acts as a danger signal. IL-33 is released from stressed or necrotic cells. Initially, IL-33 was described as an inducer of the humoral immune response, which activated Th2 cells and mast cells involved in modulating inflammation and allergic reactions. In addition, IL-33 acts as a stimulator of the Th1, NK, and CD8T cells, which induce a cytotoxic immune response against intracellular pathogens. It was recently discovered that this cytokine is involved in the development of cancer by performing both pro- and antitumor functions. IL-33 can directly affect tumor cells and provokes their proliferation, survival, and metastasis. Moreover, IL-33 stimulates carcinogenesis by remodeling the tumor microenvironment and inducing angiogenesis, thus contributing to the generation of immunosuppressive conditions. At the same time, IL-33 causes tumor infiltration with cytotoxic CD8 T lymphocytes and natural killers, which leads to cytolysis-mediated cancer cell death. This review describes the versatile role of the IL-33/ST2 cascade in the development of experimental and clinical tumors. In addition, we discuss the prospects for the application of IL-33 and ST2 as diagnostic biomarkers and targets for cancer immunotherapy.


Assuntos
Imunoterapia/métodos , Interleucina-33/imunologia , Neoplasias/imunologia , Neoplasias/patologia , Evasão Tumoral/imunologia , Humanos , Neoplasias/irrigação sanguínea , Neoplasias/diagnóstico , Neovascularização Patológica , Microambiente Tumoral/imunologia
18.
Rev. Pesqui. (Univ. Fed. Estado Rio J., Online) ; 11(5): 1180-1187, out.-dez. 2019.
Artigo em Inglês, Português | LILACS, BDENF - Enfermagem | ID: biblio-1022214

RESUMO

Objetivo: Analisar a trajetória percorrida pelas crianças e adolescentes da suspeição à confirmação diagnóstica de câncer. Métodos: Pesquisa qualitativa, desenvolvida em 2017, com entrevistas semiestruturadas junto a 19 familiares cuidadores de crianças e adolescentes com câncer, cujos dados foram submetidos à análise temática. Resultados: A trajetória de crianças e adolescentes é iniciada a partir de múltiplas e inespecíficas alterações clínicas e de desenvolvimento no âmbito sociofamiliar, posteriormente elas percorrem inúmeros serviços de saúde e são submetidas a diversos procedimentos biomédicos. Nesse caminho, barreiras no acesso aos serviços de saúde na busca pelo diagnóstico do câncer foram evidenciadas. Conclusão: É imprescindível que o sistema de saúde atenda as necessidades da população infantojuvenil em todos os seus níveis, incluindo o acesso adequado ao diagnóstico precoce do câncer, assim como melhor formação dos profissionais para a detecção. Garantindo, assim, o direito à saúde na perspectiva da integralidade do cuidado


Objective: The study's goal has been to analyze the trajectory of children and adolescents from cancer suspicion to its confirmed diagnosis. Methods: It is a descriptive-exploratory research with a qualitative approach, which was performed in 2017 through semi-structured interviews of 19 family caregivers of children and teenagers with cancer diagnosis. The data were subjected to thematic analysis. Results: Both children and adolescents' trajectories start from multiple and unspecific clinical and development alterations in the socialfamily settings, following that they go through countless healthcare services and are subjected to a variety of biomedical procedures. Along this path, there were evidenced barriers of access to healthcare services in the cancer diagnosis pursue. Conclusion: It is crucial that the healthcare system go towards attending the necessities of children and adolescents' population in all levels, including the appropriated access to an earlier diagnosis of cancer, and a better qualification of healthcare professionals for cancer detection. Hence, ensuring the right to health care under the care completeness standpoint


Objetivo: Analizar la trayectoria recorrida por los niños y los adolescentes de sospecha de confirmación diagnóstica del cáncer. Métodos: Pesquisa cualitativa, desarrollada en 2017, con entrevistas semiestructuradas junto a diecinueve familiares cuidadores de niños y adolescentes con cáncer, donde los dados han sido sometidos al analice temática. Resultados: La trayectoria de los niños y adolescentes empieza a partir de varias e inespecíficas alteraciones clínicas y del desarrollo en el ámbito sociofamiliar, posteriormente ellas recogen inúmeros servicios de salud y son sometidas a diversos procedimientos biomédicos. En este camino, barreras en el acceso a los servicios de salud en la busca por el diagnóstico del cáncer fueron evidenciadas. Conclusión: Es imprevisible que el sistema de salud atienda las necesidades de la población infantojuvenil en todos los niveles, incluyendo el acceso adecuado al diagnóstico precoz del cáncer, así como mejor formación de los profesionales para la detección. Garantizando, así, el derecho a la salud en la perspectiva de la integralidad del cuidado


Assuntos
Humanos , Masculino , Feminino , Pré-Escolar , Criança , Adolescente , Adulto , Saúde da Criança , Saúde do Adolescente , Detecção Precoce de Câncer , Neoplasias/diagnóstico , Brasil , Cuidadores
20.
J Registry Manag ; 46(1): 15-18, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31490917

RESUMO

Information on cancer stage at diagnosis is largely missing or poorly documented among population-based cancer registries in sub-Saharan Africa (SSA). In an early field trial of Essential TNM staging, it was observed that some training was needed to enable cancer registrars to abstract the correct TNM from case records. In November 2018, the Addis Ababa City Cancer Registry hosted a training course attended by 17 participants from 16 cancer registries in SSA. The participants were asked to stage 16 cancer cases (from anonymized photocopies of case records obtained from the Global Initiative for Cancer Registry Development) before and after the training. The discrepancy of the stages from before and after were scored and compared. Results showed that there was a substantial improvement in the participants' performance after the training. The application of the Essential TNM staging system, with training in its use, would allow cancer registrars in SSA to abstract cancer stage at diagnosis in a clinically recognized format, which is crucial for cancer control and public health care policy making.


Assuntos
Estadiamento de Neoplasias/normas , Neoplasias/classificação , Neoplasias/patologia , África , Avaliação Educacional , Humanos , Neoplasias/diagnóstico , Avaliação de Programas e Projetos de Saúde , Sistema de Registros
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA